Acquiring Company
H&H Bio
Acquired Company
HUMIC
South KoreaSouth KoreaBiotechnologyHealth CareBiotechnologyHealth CareArtificial IntelligenceDescription
H&H Bio has finalized its absorption-type merger with HUMIC, with H&H Bio as the surviving entity. This merger is expected to create a comprehensive non-clinical CRO service system, enhancing capabilities in drug development. The integration aims to reduce development timelines and management costs while improving business competitiveness. HCT remains the largest shareholder post-merger.
M&A Insights
Based on deal dataFrequently asked
Who acquired HUMIC?
HUMIC was acquired by H&H Bio, based in South Korea. The deal was reported on August 8, 2026. H&H Bio specializes in non-clinical contract research organization (CRO) services. The company focuses on efficacy evaluation in new drug development and has shown rapid growth recently. H&H Bio is privately held and operates in Biotechnology.
When did H&H Bio acquire HUMIC?
H&H Bio's acquisition of HUMIC was reported on August 8, 2026. H&H Bio has finalized its absorption-type merger with HUMIC, with H&H Bio as the surviving entity. This merger is expected to create a comprehensive non-clinical CRO service system, enhancing capabilities in drug development. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does HUMIC do?
HUMIC is a company that specializes in non-clinical efficacy evaluation using humanized mouse models and AI pathology analysis technology. The firm recorded profitable sales in recent years, indicating strong market demand. It is privately held, operating in Biotechnology, and is based in South Korea.